Phil Carey

Technology investor and publisher

[Phil Carey @insidemarket1]

In Japan, a million people have shut themselves in their rooms. One mother is helping them come out https://t.co/QVV81bkn60

[Phil Carey @insidemarket1]

China approves Oz digital health company @Uscom BP+ device.

Uscom [ASX:UCM} specialises in circulation delivering, non-invasive cardiovascular/pulmonary monitoring devices.

Watch recent interview CEO Rob Phillips here.

https://t.co/ZGmEOc270I

[Phil Carey @insidemarket1]

Why is this company trading at all time lows despite its progress? - https://t.co/54Lutm0kPv

[Phil Carey @insidemarket1]

Conversation 182: Icetana trading at all-time lows yet this video anomoly detection company has come a long way since then. https://t.co/x4VT9uytkC

[Phil Carey @insidemarket1]

ICTYMI Could Amazon become a chip maker and what is edge computing - https://t.co/z7wUJraUAc

[Phil Carey @insidemarket1]

Could Amazon become a chip maker and what is edge computing - *|https://t.co/bS7PoWMSHk|*

[Phil Carey @insidemarket1]

Part 2 of conversation 181: Edge Computing and what many AI investors are missing. https://t.co/eMOJ4dOTBu

[Phil Carey @insidemarket1]

Conversation 181: The business case for investing in AI and which investment areas to look at. https://t.co/iiqLFPcCE8

[Phil Carey @insidemarket1]

Conversation 179: Medadvisor says business is well undervalued. https://t.co/cx6z1MCwoc

[Phil Carey @insidemarket1]

Conversation 176: The strategy behind the creation of Vection Technologies could be one of the most astute I’ve seen and here’s why. https://t.co/PjJKJRTqzq

[Phil Carey @insidemarket1]

Conversation 175: Forget tea leaf reading - the real money is in plate reading. https://t.co/fKFjJhhvAA

[Phil Carey @insidemarket1]

Conversation 180: Straker Translations. Is it time to pay attention to this hybrid SaaS business? https://t.co/SYNFDofNoZ

[Phil Carey @insidemarket1]

Conversation 180: Straker Translations. Is it time to pay attention to this hybrid SaaS business? https://t.co/d3B18DaVDH

[Phil Carey @insidemarket1]

A 30% share price dilution in return for 196% increase in revenue has CEO @medadvisor smiling. "That's some maths that I quite like," Robert Read told me.

He explains how biz ASX:MDR is mispriced explains why.

Full interview at https://t.co/FKBW69ken9

[Phil Carey @insidemarket1]

The business strategy behind Vection Technologies is one of the most astute we've seen. https://t.co/VebDh4Kej3

[Phil Carey @insidemarket1]

Forget tea leaf reading - the real money is in plate reading, as the march of digitisation and technology convergence in health is advancing at an astounding rate and how tech investors see this business as a hot topic. Find out more here.
https://t.co/GwjPJADP3R

[Phil Carey @insidemarket1]

How can you have a faster better and cheaper product and not sell a s*@#t load of it? - https://t.co/FLD8Rn2B5U

[Phil Carey @insidemarket1]

How can you have a faster better and cheaper product and not sell a s*@#t load of it? Find out which anti-counterfeiting, authentication and tracing solutions business appears to have turned the commercial corner.
https://t.co/sTA97zHAEe

[Phil Carey @insidemarket1]

It is a testing time for this digital pregnancy monitoring solution.
Find out why the next couple of weeks could be pivotal for HeraMED and its Mayo Clinic partner.
https://t.co/kWjkgPzVIj

[Phil Carey @insidemarket1]

Australia's DroneShield is kicking some series technology goals internationally. But weirdly Morningstar has the company undervalued by ~40%. However the CEO is predicting big dollars through the door in the next few months. https://t.co/DJnSNMZQtI